- Sinovac’s covid-19 vaccine efficacy declines to 28% against both Covid-19 infection and ICU admission within three to five months after full vaccination.
- Sinovac’s breakthrough fatality risk is the greatest of the three Covid-19 vaccines at 34 per million people, compared to Pfizer’s at 9.8 per million people and AstraZeneca’s at six per million people.
Sinovac Vaccine Efficacy Plummets To 28% in 3 to 5 Months Studies Reveal
On Wednesday (Nov 24), health news website CodeBlue reported that the two-dose Sinovac vaccine’s efficacy against Covid-19 infection had also decreased to 28% from 76% in 3 to 5 months, citing research by the Real-World Evaluation of Covid-19 Vaccines Under the Malaysian National Covid-19 Immunisation Programme (RECoVaM) and the National Medical Research Register (NMRR).
In comparison, it said that Pfizer’s two-dose Covid-19 vaccine remained 79% effective at reducing ICU admission three to five months after the primary vaccination, down from 86%.
However, when it came to protecting against Covid-19 infection, Pfizer’s vaccination effectiveness decreased from 89% to 68% during the same time period.
source - edge prop
Additionally, the study revealed that Sinovac’s Covid-19 vaccine was only 76% effective against breakthrough fatalities three to five months after the primary series, down from 79% two months later.
In comparison, after five months, Pfizer’s Covid-19 vaccination remained 91% effective against breakthrough fatalities.
Between June 7 and November 15, 2021, Sinovac had an average weekly adult death rate of two per 100,000 population, compared to Pfizer’s weekly adult death rate of 0.667 per 100,000 population and AstraZeneca’s weekly adult death rate of 0.25 per 100,000 population.
It said, however, that unvaccinated fatalities dominated, with an average of 22.354 adult deaths per 100,000 population each week during the same 24-week period.
It said that according to data collected by consultant paediatrician Dr Amar-Singh HSS from Nov 1 to 20, 2021, unvaccinated individuals are 14.5 times more likely to die from the virus than fully vaccinated people.
According to CodeBlue, Dr Amar arrived at this conclusion after tallying the 827 Covid-19 adult deaths reported over a 20-day period — 315 unvaccinated, 41 partially vaccinated, and 471 fully vaccinated — against the adult population’s unvaccinated (1.03 million), partially vaccinated (526,632), and fully vaccinated (22.38 million).
According to the report, the mortality rate among unvaccinated adults was 305.2 per million population from November 1 to 20, compared to 77.9 per million and 21.1 per million for the partly and fully vaccinated populations, respectively.
Among the 471 fully vaccinated adult fatalities documented throughout the time, 332 were Sinovac recipients, 127 were Pfizer double vaccine recipients, and 12 received two AstraZeneca doses.
Dr Amar discovered that Sinovac’s breakthrough fatality risk is the greatest of the three Covid-19 vaccines at 34 per million people, compared to Pfizer’s at 9.8 per million people and AstraZeneca’s at six per million people.